With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4318-42-7,1-Isopropylpiperazine,as a common compound, the synthetic route is as follows.
d) 1-(5-fftert-butyldimethylsilyloxy)methynpyridin-2-yl)piperidin-4-yl4- isopropyl-piperazine-1-carboxylate To a solution of 1-(5-((tert-butyldimethylsilyloxy)methyl)pyridin-2-yl)- piperidin-4-ol (257 mg, 1 mmol) in DCM (8 mL) was added BTC (297 mg, 1 mmol) and Et3N (152 mg, 1.5 mmol). The mixture was stirred at rt for 1 h before 1-isopropylpiperazine (128 mg, 1 mmol) was addedand the resulting mixture was stirred at rt overnight. The mixture was diluted with DCM (20 mL), washed with saturated K2C03?(20 mL) solution and brine (20 mL), dried andconcentrated to give the desired product as yellow oil (350 mg, 74percent). [LCMS: RtA?= 1.95min, m/z 477.2 [M+H]+].
4318-42-7, As the paragraph descriping shows that 4318-42-7 is playing an increasingly important role.
Reference£º
Patent; NOVARTIS AG; WANG, Tielin; ZHANG, Xuechun; WO2013/50987; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics